# OnCo record malt-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/malt-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "malt-lymphoma" ;
  schema:name "Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)"@en ;
  schema:alternateName "MALT lymphoma"@en, "Mucosa-associated lymphoid tissue lymphoma"@en, "Extranodal marginal zone lymphoma"@en, "Extranodal marginal zone lymphoma of MALT"@en, "Gastric MALT lymphoma"@en, "Ocular adnexal MALT lymphoma"@en, "Orbital lymphoma (mostly MALT type)"@en, "Extranodal marginal zone lymphoma of MALT (gastric, ocular adnexal, salivary, thyroid, lung, skin)"@en ;
  schema:description "MALT lymphoma is a slow-growing lymphoma that starts in lymphoid tissue lining an organ, most often the stomach, where it is usually caused by long-standing Helicobacter pylori infection and can be cured with antibiotics alone. Other sites include the eye socket, salivary glands, thyroid, lung and skin; localised disease is treated with low-dose radiotherapy and widespread disease with rituximab."@en ;
  schema:url <https://onco.cc/cancers/malt-lymphoma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/MALT_lymphoma> ;
  schema:citation <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>, <https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1016/j.annonc.2019.10.010>, <https://doi.org/10.1007/s00277-014-2298-3>, <https://doi.org/10.1016/j.clml.2019.10.006> ;
  onco:tag "subtype-page", "wave4", "haematologic", "rare" ;
  onco:related <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/nodal-marginal-zone-lymphoma/>, <https://onco.cc/cancers/primary-cutaneous-marginal-zone-lymphoma/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/myeloid-leukaemia-of-down-syndrome/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/orelabrutinib/>, <https://onco.cc/drugs/umbralisib/> ;
  onco:trials <https://onco.cc/trials/fort/>, <https://onco.cc/trials/augment/>, <https://onco.cc/trials/zuma-5/>, <https://onco.cc/trials/nct05100862/>, <https://onco.cc/trials/nct06082102/> ;
  onco:standardOfCare <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/trials/fort/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/trials/augment/>, <https://onco.cc/trials/nct05100862/> .